Stock Yards Bank & Trust Co. Has $17.15 Million Stock Position in Johnson & Johnson $JNJ

Key Points

• Stock Yards Bank & Trust Co. reduced its stake in Johnson & Johnson by 8.7%, now holding 112,266 shares valued at approximately $17.15 million.
• Several institutional investors increased their holdings in Johnson & Johnson in Q1, indicating a strong interest in the stock, which is primarily held by institutional investors (69.55%).
• Johnson & Johnson's stock price recently rose 1.4%, and the company announced a quarterly dividend of $1.30 per share, reflecting a 2.8% yield.

Stock Yards Bank & Trust Co. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 8.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 112,266 shares of the company's stock after selling 10,729 shares during the period. Stock Yards Bank & Trust Co.'s holdings in Johnson & Johnson were worth $17,149,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of JNJ. Elios Financial Group Inc. increased its stake in shares of Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after acquiring an additional 66 shares during the last quarter. Atlantic Family Wealth LLC increased its stake in Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after purchasing an additional 67 shares in the last quarter. MBA Advisors LLC raised its holdings in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares during the period. Nabity Jensen Investment Management Inc boosted its position in shares of Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares in the last quarter. Finally, Jackson Grant Investment Advisers Inc. grew its holdings in shares of Johnson & Johnson by 0.5% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 12,970 shares of the company's stock valued at $2,151,000 after buying an additional 69 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HSBC lifted their target price on Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. UBS Group set a $198.00 price target on shares of Johnson & Johnson in a report on Friday. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an "overweight" rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $188.88.

Johnson & Johnson Stock Up 1.4%

Johnson & Johnson stock opened at $188.51 on Monday. The company has a fifty day simple moving average of $176.18 and a 200 day simple moving average of $162.83. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $189.78. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company has a market cap of $453.98 billion, a P/E ratio of 20.16, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.